Innate Pharma Presents Preclinical Efficacy Of Its Pre-IND Drug Candidate IPH45, A Novel Nectin-4 Antibody Drug Conjugate At AACR 2024
$IPHA
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- IPH45 is a novel and differentiated exatecan-Antibody Drug Conjugate targeting Nectin-4
- In PDX models of urothelial tumors, IPH45 has stronger activity than approved Nectin-4 targeting EV. IPH45 shows anti-tumor efficacy in various solid tumor and EV-refractory models
- Preclinical efficacy and toxicology data support further development of IPH45 which is progressing towards the clinic with IND planned in 2024